January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 ...

Novo Nordisk (NVO) has reportedly been criticized by the U.K.'s Prescription Medicines Code of Practice Authority, or PMCPA, for mischaracterizing certain payments to patients and healthcare groups.

Novo Nordisk (NVO) has reportedly been criticized by the U.K.'s Prescription Medicines Code of Practice Authority, or PMCPA, for mischaracterizing certain payments to patients and healthcare ...

Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

Novo Nordisk (NYSE: NVO) is working with Durham-based IMMvention Therapeutix to jointly develop oral therapies for the disease and other chronic conditions. The companies did not disclose the ...

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.

IMMvention partners with Novo Nordisk to co-develop oral therapies for sickle cell disease using BACH1 inhibitors. Novo Nordisk to handle further development, regulatory, and commercialization ...